貨號
產(chǎn)品規(guī)格
售價(jià)
備注
BN40906R-100ul
100ul
￥2470.00
交叉反應(yīng)：Human,Mouse(predicted:Rat) 推薦應(yīng)用：WB,IHC-P,IHC-F,IF,ELISA
產(chǎn)品描述
| 英文名稱 | Phospho-RPS6KA1 (Thr573) |
| 中文名稱 | 磷酸化絲氨酸/蘇氨酸激酶p90RSK蛋白抗體 |
| 別 名 | p90RSK (Phospho Thr573); Rsk 1 / MAPKAP Kinase 1a (phospho T573); p-Rsk 1 / MAPKAP Kinase 1a (phospho T573);p90 RSK1; p90rsk; p90S6K; pp90RSK1; Ribosomal protein S6 kinase 90kD 1; Ribosomal protein S6 kinase 90kD polypeptide 1; Ribosomal protein S6 kinase 90kDa polypeptide 1; Ribosomal protein S6 kinase alpha 1; Ribosomal protein S6 kinase polypeptide 1; Ribosomal S6 kinase 1; RPS6K1 alpha; rps6ka; Rps6ka1; RSK 1; RSK 1 p90; RSK; RSK1; S6K alpha 1; 90 kDa ribosomal protein S6 kinase 1; dJ590P13.1 (ribosomal protein S6 kinase, 90kD, polypeptide 1; dJ590P13.1; EC 2.7.11.1; HU 1; HU1; MAP kinase activated protein kinase 1a; MAPKAP kinase 1A; MAPKAPK1A; MGC79981; Mitogen-activated protein kinase-activated protein kinase 1A; OTTHUMP00000004113. |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 信號轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, (predicted: Rat, ) |
| 產(chǎn)品應(yīng)用 | ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=0.2ug/test IF=1:100-500 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 81kDa |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human p90RSK around the phosphorylation site of Thr573:LM(p-T)P |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | Rsk1 is a member of a family of 90kDa ribosomal protein S6 kinases, which includes Rsk1, Rsk2 and Rsk3. These are broadly expressed serine/threonine protein kinases activated in response to mitogenic stimuli, including extracellular signal regulated protein kinases Erk1 and Erk2. Rsk1 is activated by MAPK in vitro and in vivo via phosphorylation. Active Rsks appear to play a major role in transcriptional regulation by translocating to the nucleus and phosphorylating c Fos and CREB. Function: Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1, which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. Subunit: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in quiescent cells. Transiently dissociates following mitogenic stimulation. Interacts with ETV1/ER81 and FGFR1. Subcellular Location: Nucleus. Cytoplasm. Post-translational modifications: Activated by phosphorylation at Ser-221 by PDPK1. Autophosphorylated on Ser-380, as part of the activation process. May be phosphorylated at Thr-359 and Ser-363 by MAPK1/ERK2 and MAPK3/ERK1. N-terminal myristoylation results in an activated kinase in the absence of added growth factors. Similarity: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. S6 kinase subfamily. Contains 1 AGC-kinase C-terminal domain. Contains 2 protein kinase domains. SWISS: Q15418 Gene ID: 6195 Database links: Entrez Gene: 6195 Human Entrez Gene: 20111 Mouse Omim: 601684 Human SwissProt: Q15418 Human SwissProt: P18653 Mouse Unigene: 149957 Human Unigene: 301827 Mouse Unigene: 34915 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. p90RSK蛋白屬于廣泛表達(dá)的絲氨酸/蘇氨酸激酶。RSK家族包括RSK1、RSK2、RSK3和RSK4，它們的典型特征是含有兩個(gè)不同的功能性激酶結(jié)構(gòu)域和羧基端ERKs(extracellular signal-regulated kinases)結(jié)合結(jié)構(gòu)域。RSK激酶結(jié)構(gòu)域內(nèi)外的幾個(gè)位點(diǎn)包括Ser380、Thr359、Ser363和Thr573的磷酸化都對RSK的激酶活性激活非常重要。 RSK1-3可被MAPKs所磷酸化激活，也可以通過自身磷酸化激活，還可被一些生長因子或神經(jīng)遞質(zhì)等誘導(dǎo)激活的PI3K信號通路所激活。RSK在被MAPK磷酸化激活時(shí)，是由Ras、Raf-1、MAP kinase kinase(MEK)和MAP kinase信號通路所介導(dǎo)。PI3K誘導(dǎo)的RSK1激活是由絲氨酸/蘇氨酸激酶mTOR介導(dǎo)的。 RSK1在葡萄糖穩(wěn)態(tài)調(diào)控和細(xì)胞大小的調(diào)控中起重要作用。RSK可以磷酸化并調(diào)節(jié)轉(zhuǎn)錄因子c-fos和糖原合成酶激酶3(GSK3,glycogen synthase kinase 3)的活性。有報(bào)道RSK1可以和MAPK1、IκBα、TOB和TSC2等相互作用。RSK可以在有絲分裂信號刺激下會轉(zhuǎn)位到細(xì)胞核內(nèi)。 |
在線咨詢
English
